



Contact: Heather Hatfield
781-681-2124

News Release

May 3, 2010

EMD Serono, Inc. Named One of the Best Places to Work in Industry by *The Scientist* Magazine

- **EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, ranked No. 24 among the top life sciences organizations in biotech/pharma**

Rockland, MA, May 3, 2010 – EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced it has been named as one of the best places to work in the industry by *The Scientist* magazine. EMD Serono ranked number 24 among the top institutions; more than 240 companies participated in the survey overall.

“It’s an honor to earn recognition from *The Scientist* as one of the top companies to work for in the industry,” said Bernhard Kirschbaum, Head of Global Research and Development, Merck Serono, a division of Merck KGaA, Darmstadt, Germany. “It is the commitment, focus and world-class expertise of our employees that truly makes a difference to not only our organization, but to patients living with unmet medical needs. Our employees play a critical role in ensuring that we strengthen our reputation as a leader in the industry, and continue our mission of advancing science and medicine.”

EMD Serono’s scores reflected the company’s commitment to its employees, with high marks in the areas of remuneration and benefits, and training and development.

“EMD Serono’s ranking on *The Scientist’s* Best Places to Work listing is an important independent marker that confirms that we are reaching our goal to become a top employer in the US biopharmaceutical market,” says Fereydoun Firouz, President and



News Release

CEO of EMD Serono, Inc. “One of our key priorities is to maintain and improve our company standing as ‘the place to be.’ With an expansion of our research organization in Billerica, Massachusetts/USA close to completion, we are on track on our dual stream to deliver our commitment to our employees and advance the discovery and development of new, promising treatments for patients.”

The Scientist's May issue is available now in print and online.

About EMD Serono, Inc.

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives. The company has strong market positions in neurodegenerative diseases, with Rebif® (interferon beta-1a), as well as in endocrinology, with Saizen® (somatropin (rDNA origin) for injection) and Serostim® (somatropin (rDNA origin) for injection). EMD Serono is a leader in reproductive health, with Gonal-f® (follitropin alfa for injection), Luveris® (lutropin alfa for injection) and Ovidrel® Prefilled Syringe (choriogonadotropin alfa injection). With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono's US footprint continues to grow, with more than 1100 employees around the country and fully integrated commercial, clinical and research operations in the company's home state of Massachusetts.

For more information, please visit www.emdserono.com

About Merck KGaA

Merck KGaA is a global pharmaceutical and chemical company with total revenues of € 7.7 billion in 2009, a history that began in 1668, and a future shaped by approximately 33,000 employees in 61 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

For more information, please visit www.merckserono.com or www.merck.de